医美产品研发商Acclaro Medical筹集了2300万美元B轮融资，以推进突破性的2910纳米光纤激光技术-动脉网

Acclaro Medical Raises $23 Million in Series B Funding Led by Accelmed Partners to Advance Groundbreaking 2910 nm Fiber Laser Technology

CISION 等信源发布 2025-05-29 19:17



可切换为仅中文







Accelmed

$20 Million

2000万美元

Investment with 3E Bioventures Capital Funding of

与3E Bioventures Capital Funding的投资

$3 Million

300万美元

to Drive Innovation, Clinical Expansion, and Global Market Growth

推动创新、临床扩展和全球市场增长

SMITHFIELD, R.I.

史密斯菲尔德，罗德岛州

，

May 29, 2025

2025年5月29日

/PRNewswire/ --

Acclaro Medical

阿克拉罗医疗

, a pioneering medical technology company focused on developing cutting-edge solutions that improve patient care and redefine medical practices, proudly announces the successful completion of its Series B funding round. Led by

，一家专注于开发改善患者护理和重新定义医疗实践的前沿解决方案的先锋医疗技术公司，自豪地宣布其B轮融资成功完成。本轮融资由

Accelmed Partners

Accelmed合作伙伴

with participation by existing investor

现有投资者参与其中

3E Bioventures Capital

三一生物风险投资公司

, the combined funding of

，联合资助

$23 million

2300万美元

marks a pivotal milestone in the company's journey to fulfill unmet aesthetic needs through its

标志着公司在通过其满足未被满足的美学需求的旅程中达到了一个关键的里程碑，

innovative 2910 nm fiber laser solution

创新的2910纳米光纤激光解决方案

and other disruptive technologies. This capital infusion will help Acclaro accelerate the growth of its flagship products,

以及其他颠覆性技术。这笔资金的注入将有助于Acclaro加速其旗舰产品的增长，

UltraClear

超清晰

and

和

AuraLux

™

and expedite global market expansion while advancing development of new trailblazing products in its pipeline.

加快全球市场扩张，并推进其研发管道中新的开创性产品的开发。

继续阅读

Acclaro Medical's UltraClear fiber laser is recognized by

Acclaro Medical的UltraClear光纤激光器被认可

leading aesthetic professionals

领先的美学专业人士

as a breakthrough in

作为一项突破性进展在

Total Skin Health

全身皮肤健康

that treats multiple skin layers to help reverse the signs of aging and

针对多层皮肤进行处理，有助于逆转衰老迹象并

gravity.

重力。

The first of its kind

前所未有的

2910 nm cold ablative fiber laser

2910纳米冷消融光纤激光器

, powered by proprietary 3DIntelliPulse

，由专有的3DIntelliPulse提供动力

™

technology, delivers:

技术，提供：

'The funding is a testament to our unstoppable team and tremendous progress Acclaro has made in a very short duration.'

“这笔资金证明了我们不可阻挡的团队和Acclaro在非常短的时间内取得的巨大进步。”

Post this

发布这个

Unparalleled clinical efficacy

无与伦比的临床疗效

Superior patient experiences

卓越的患者体验

Unmatched versatility

无与伦比的多功能性

Significantly

显著地

improved safety for all skin types

适用于所有肤质的更安全选择

, including previously high-risk skin-of-color patients.

，包括之前高风险的有色人种患者。

Its precision-engineered capabilities make it the ideal choice for practitioners seeking

其精密设计的能力使其成为寻求的从业者的理想选择

transformative results

变革性的成果

with

minimal downtime

最小停机时间

，

reduced patient discomfort

减少患者不适

and

和

speedy healing

快速愈合

. Complementing UltraClear, the AuraLux laser leverages the same exclusive Cool Pulse

配合UltraClear，AuraLux激光器利用了同样独特的Cool Pulse

™

technology and broadens accessibility for aesthetic providers and their patients while maintaining Acclaro's hallmark quality.

技术和拓宽了美容服务提供者及其患者的可及性，同时保持了Acclaro标志性的质量。

'Securing this Series B investment is a powerful testament to our unstoppable team and the tremendous progress that Acclaro has made in a very short period of time,' said Acclaro Medical CEO and Co-founder

“获得这笔B轮融资充分证明了我们团队的不懈努力，以及Acclaro在极短时间内取得的巨大进展，”Acclaro Medical首席执行官兼联合创始人表示。

Helen Fang

方海伦

. 'This funding empowers us to continue our strong growth and realize our vision of improving the quality of life for people of all skin colors and all ages worldwide.'

“这笔资金使我们能够继续保持强劲的增长，并实现我们改善全球所有肤色和所有年龄段人群生活质量的愿景。”

Shlomo Assa

施洛莫·阿萨

, President and co-founder of Acclaro Medical, noted: 'We are thrilled to have the support of Accelmed as we expand our global and domestic footprint. This Series B funding is a strong vote of confidence in our mission to bring UltraClear and AuraLux to more people pursuing anti-aging solutions for .

Acclaro Medical的总裁兼联合创始人表示：“在我们扩大全球和国内的业务范围时，能够得到Accelmed的支持，我们感到非常兴奋。此次B轮融资对我们实现将UltraClear和AuraLux带给更多寻求抗衰老解决方案的人们的使命，是一次强有力的肯定。”

healthier and younger-looking skin

更健康、更年轻的皮肤

. It greatly enables us to accelerate product development, expand our team, and reach more customers globally – And we're just getting started!'

它极大地帮助我们加速产品开发、扩大团队规模，并在全球范围内接触更多客户——而且我们才刚刚开始！

The Series B funding will allow Acclaro Medical to leverage decades of Accelmed's operational and financial expertise, alongside 3E Bioventures' disciplined efficiency. Acclaro Medical is poised to execute its strategic plans and realize its vision of revolutionizing the aesthetic industry. These efforts will further cement the company's position as a leader in providing innovative, patient-centered skin health solutions..

B轮融资将使Acclaro Medical能够利用Accelmed数十年的运营和财务专业知识，以及3E Bioventures的严谨效率。Acclaro Medical已准备好执行其战略计划，实现其革新美容行业的愿景。这些努力将进一步巩固该公司作为提供创新的、以患者为中心的皮肤健康解决方案的领导地位。

'Acclaro's unique cold laser fiber technology constitutes a game changer in laser aesthetics with the possibility for aesthetic practices to safely treat all skin types for all major indications using only one device,' stated

“Acclaro独特的冷激光光纤技术在激光美学领域带来了颠覆性的变革，使得美容机构能够使用单一设备安全地治疗所有肤质的主要适应症。”

Daniel Cohen

丹尼尔·科恩

, Accelmed's venture partner with extensive experience leading successful Medtech & Biotech investments over the last 20 years. 'Accelmed Partners is thrilled to lead this round of financing and accompany Acclaro' s management in this fantastic journey.'

，Accelmed的风险合作伙伴，在过去20年中拥有领导成功的医疗技术和生物技术投资的丰富经验。'Accelmed Partners很高兴能够主导此轮融资，并陪伴Acclaro的管理层踏上这一美妙的旅程。'

About Acclaro Medical

关于Acclaro Medical公司

Founded in 2018 by world-class industry experts, Acclaro Medical is committed to developing, innovating and bringing to market game-changing solutions to address today's unmet medical, aesthetic and surgical practice needs. With a relentless commitment to innovation and a team of dedicated professionals, Acclaro Medical continues to push the boundaries and drive positive change in the aesthetic medical industry.

Acclaro Medical 由世界级行业专家创立于2018年，致力于开发、创新并推出革命性的解决方案，以满足当今未被满足的医疗、美容和外科实践需求。凭借对创新的不懈追求和一支专注的专业团队，Acclaro Medical持续突破界限，推动美容医疗行业的积极变革。

Its proprietary 3DMIRACL.

其专有的3DMIRACL。

™

and Laser Coring

激光钻孔

™

skin rejuvenation treatments are valued for offering unrivaled aesthetic results complemented by high patient comfort, rapid healing and utmost safety across all skin types. For more information, please visit

皮肤再生治疗因其无与伦比的美学效果而备受推崇，同时兼顾患者高舒适度、快速愈合和所有肤质的最高安全性。欲了解更多信息，请访问

https://ultraclearlaser.com/about/acclaro-medical/

。

About Accelmed Partners

关于Accelmed合作伙伴

Accelmed, a leader in healthcare technology investing, is renowned for its private equity approach to a sector traditionally dominated by venture and early-stage growth firms. Its team of experienced industry veterans and company builders work closely as a trusted partner with portfolio management to improve operations, upgrade product portfolios, and strengthen commercial organizations.

Accelmed是一家在医疗技术投资领域的领导者，以其在传统上由风险投资和早期成长型公司主导的行业中采用的私募股权方法而闻名。其经验丰富的行业资深人士和公司建设者团队与投资组合管理方紧密合作，作为值得信赖的合作伙伴，改善运营、升级产品组合并增强商业组织实力。

Accelmed's support and resources are designed to help portfolio companies like Acclaro Medical elevate its technology and achieve enduring success. The investment firm currently manages over .

Accelmed的支持和资源旨在帮助像Acclaro Medical这样的投资组合公司提升其技术并取得持久的成功。该投资公司目前管理着超过。

$630 million

6.3亿美元

of equity capital. For more information, please visit

权益资本。欲了解更多信息，请访问

https://accelmed.com/about

。

Media Contact:

媒体联系人：

Nadine Tosk

纳丁·托斯克

Tosk Communications for Acclaro Medical